Johnson & Johnson (JNJ) Covered Calls

Johnson & Johnson covered calls Johnson & Johnson is a global healthcare leader focused on innovative medicine and medical technology. The company develops and manufactures pharmaceutical products for oncology, immunology, and neuroscience, alongside advanced medical devices for cardiovascular, surgical, and orthopedic care. Following the separation of its consumer health business, the firm operates as a pure-play healthcare giant dedicated to delivering smarter, less invasive, and more personalized medical solutions.

You can sell covered calls on Johnson & Johnson to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for JNJ (prices last updated Wed 4:16 PM ET):

Johnson & Johnson (JNJ) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
234.47 +1.37 232.50 234.52 8.6M 23 562
Covered Calls For Johnson & Johnson (JNJ)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Feb 20 235 3.60 230.92 1.6% 34.4%
Mar 20 230 8.60 225.92 2.4% 19.5%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

Core Business and Products

Johnson & Johnson (J&J) is one of the largest and most diversified healthcare companies in the world. Since its 2023 spin-off of the Kenvue consumer health division, the company has operated through two primary, high-growth segments: Innovative Medicine and MedTech. This transformation has sharpened its focus on high-margin, science-driven segments of the health market.

  1. Innovative Medicine: This division represents the company's pharmaceutical arm. It specializes in complex therapeutic areas, including Oncology (led by the blockbuster multiple myeloma drug Darzalex), Immunology (transitioning from Stelara to next-generation treatments like Tremfya and icotrokinra), and Neuroscience. In 2026, the company is prioritizing "Cell Therapy" and "Antibody-Drug Conjugates" to target cancer cells with pinpoint precision.
  2. MedTech: J&J's medical technology segment is a world leader in surgical, cardiovascular, and vision care. Recent multi-billion dollar acquisitions, such as Shockwave Medical and Abiomed, have solidified its position in heart recovery and circulatory restoration. In 2026, the company is deploying the OTTAVA robotic surgical system, designed to integrate with its existing portfolio of surgical instruments to enhance operating room efficiency.

Competitive Landscape

Johnson & Johnson competes in a highly specialized landscape where research and development (R&D) speed and patent protection are the primary barriers to entry:

  1. Pharmaceutical Rivals: In the innovative medicine space, J&J faces intense competition from Pfizer and Merck, particularly in the race for oncology leadership. In immunology, AbbVie remains a formidable rival, while biosimilar manufacturers like Amgen exert pressure on J&J's older biologics.
  2. MedTech Competitors: In the medical device arena, Medtronic and Abbott Laboratories are its most direct peers, especially in cardiovascular and neuromodulation technology. In the high-growth robotic surgery segment, Intuitive Surgical is the primary incumbent that J&J's new platforms aim to challenge.
  3. Other Healthcare Peers: The company also monitors developments from large-cap peers like Bristol Myers Squibb and Eli Lilly, which compete for market share in specialized niches like immunology and neuroscience.

Strategic Outlook and Innovation

In 2026, Johnson & Johnson is successfully navigating the "patent cliff" of its legacy blockbuster Stelara by launching a suite of differentiated assets with long regulatory runways. The company has officially entered its "100 Billion Era," forecasting annual sales to exceed that threshold for the first time. A key pillar of its 2026 strategy is the decentralization of its MedTech unit, allowing its Cardiovascular and Surgery businesses to operate with greater agility. J&J is also heavily invested in "Digital Surgery," using artificial intelligence to analyze surgical data and provide real-time guidance to doctors. By focusing on "Accountable Care" and life-saving innovation, J&J aims to maintain its status as a cornerstone of the global healthcare system while continuing its 63-year streak of dividend increases.